| FDA LABA warning: is there anything new here? | |
| | |
MedLine Citation:
|
PMID: 20485319 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The FDA advisory on long-acting beta-agonists (LABAs) is not based on new data but on ongoing safety concerns about this class of medication. Not to be ignored are the potential safety risks of short-acting beta-agonists (SABAs). |
| | |
Authors:
|
S T Weiss |
Related Documents
:
|
19552339 - The family and medical leave act: implications for occupational and environmental healt... 18018439 - Benign paroxysmal positional vertigo in an airline pilot. 19038639 - Certification, recertification, and maintenance: continuing to learn. 1587989 - The prevalence and aeromedical certification considerations of contact lens use by civi... 15182749 - The relationship of workers' compensation to the americans with disabilities act and fa... 22058069 - Cerebral palsy: the whys and hows. 10556729 - Salt stress affects sterol biosynthesis in the halophilic black yeast hortaea werneckii. 11675839 - Potential adverse drug events in an indigent and homeless geriatric population. 19666129 - When continents collide: phylogeny, historical biogeography and systematics of the medi... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Clinical pharmacology and therapeutics Volume: 87 ISSN: 1532-6535 ISO Abbreviation: Clin. Pharmacol. Ther. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-20 Completed Date: 2010-06-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0372741 Medline TA: Clin Pharmacol Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 638-9 Citation Subset: AIM; IM |
Affiliation:
|
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. scott.weiss@channing.harvard.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Inhalation Adrenergic beta-Agonists / administration & dosage, adverse effects*, therapeutic use Asthma / drug therapy Delayed-Action Preparations Drug Labeling* Glucocorticoids / administration & dosage, adverse effects, therapeutic use Humans Practice Guidelines as Topic United States United States Food and Drug Administration |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Agonists; 0/Delayed-Action Preparations; 0/Glucocorticoids |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dealing with the evidence dilemma in genomics and personalized medicine.
Next Document: Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?